An observational study in Stroke Acute, sponsored by Vesalio. Active, not recruiting at 5 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Vesalio · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Stroke with a site in Argentina — 9 open to participants now, 12 under way, 3 of them phase 3. Stroke · Argentina.
Among the 50 studies in Stroke with a site in Argentina, this one is the 5th largest by planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2025, is one of 13 observational ones, reaches primary completion later than 2 of the 11 other live ones, and was the 45th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →9 of the 50 studies in Stroke with a site in Argentina are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Argentina, Australia, Austria and 35 more countries
Ages 50+
Regeneron Pharmaceuticals · Sites in Argentina, United States, Brazil and 1 more country
Ages 18+
Ramos Mejía Hospital · Sites in Argentina
Ages 16+
McMaster University · Sites in Argentina, Canada
Ages 18+
Philips Clinical & Medical Affairs Global · Sites in Argentina, United States, Belgium and 7 more countries
Ages 18+
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 150 across 1,971 observational studies indexed under Stroke.
Median enrollment 5,390 across the 37 interventional studies, 535 across the 13 observational. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 50 have an industry lead sponsor. The 10 most frequent:
Vesalio is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Vesalio has 2 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
7 of the studies in Stroke with a site in Argentina that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07475611Fundación para la Lucha contra las Enfermedades Neurológicas de la InfanciaEffectiveness of an Interactive Screen in the Rehabilitation of Neglect in Adults With Subacute Stroke: A Randomized Controlled Trial in Argentina. | 2026-12-01 |
| NCT04562194VesalioNeVa ONE Registry Study | 2026-12-31 |
| NCT06964724VesalioNeVa Retrospective Comparative SR Study | 2027-02-01 |
| NCT07175428Regeneron PharmaceuticalsSafety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | 2027-02-09 |
| NCT04701684Philips Clinical & Medical Affairs GlobalWE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment) | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 50 studies in Stroke with a site in Argentina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare safety and effectiveness of NeVa Stent Retriever (SR) to Control SR in the treatment of stroke caused by large vessel occlusion. The main questions it aims to answer are:
How do recanalization rates for NeVa SR compare with those of the Control SR? How does NeVa SR safety compare with Control SR safety?
NITRO is a multicenter, retrospective, comparative, non-inferiority, cohort study designed to compare NeVa SR with Control SR for safety and effectiveness when removing thrombus in subjects presenting with acute ischemic stroke (AIS) due to large vessel occlusion (LVO). The objective of the NeVa International, Multi-center, Retrospective Comparative stent retriever (SR) study (NITRO) study is to compare safety and effectiveness of the NeVa SR to commonly used SR with CE-mark, and US FDA clearance, to restore blood flow in patients experiencing acute ischemic stroke due to large intracranial vessel occlusion. NITRO aims to collect data describing real-world clinical practices when using SRs according to their indicated use within the indicated population. As such, the eligibility criteria define patients who are diagnosed with AIS and are indicated for endovascular MT aligning to the target population for the proposed device. The present study will include data from subjects treated with either NeVa SR or one of the Control SR. Control SR will include any SR commonly used in thrombectomy trials as first-line strategies and which represent CE-mark, and US FDA cleared stent retrievers.
Subjects suffering from acute ischemic stroke from large vessel occlusion treated with study device.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
According to Guidelines AIS patients due to LVO should receive mechanical thrombectomy (with a stent retriever) under certain conditions.
Procedure: Mechanical thrombectomy
Mechanical thrombectomy with stent retriever
Reperfusion Effectiveness
Number of patients with a Modified Thrombolysis in cerebral infarction (mTICI) ≥2B and mTICI≥2C recanalization after 1st pass and at end of procedure
Time frame: Procedural
Procedural symptomatic bleeding events
Number of patients experiencing symptomatic intracranial hemorrhage (sICH)
Time frame: Within 24 hours post intervention
Procedure Safety
Number of patients experiencing procedure related serious Adverse Events (PRSAE)
Time frame: Within 24 hours post intervention
Device relationship to serious adverse events
Number of patients experiencing a serious adverse device effect (SADE)
Time frame: Within 24 hours post intervention
Functional Independence at 90 days
Number of patients with a Modified Rankin Scale (mRS) 0-2
Time frame: At 90 Days
90-day Mortality
Number of patients that died at 90-days from any cause
Time frame: Within 90 days post intervention
Plan to share: Undecided — At this stage not yet discussed how or at which URL the Protocol defined Endpoints will be made available.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Feb 2027, 19 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Jun 2026 → Feb 2027 and completion Sep 2026 → Feb 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vesalio